Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Emisphere Technologies Inc. stock logo
EMIS
Emisphere Technologies
$7.81
$7.81
$4.06
$9.16
N/AN/AN/AN/A
Omeros Corporation stock logo
OMER
Omeros
$3.38
+8.0%
$3.88
$2.95
$13.60
$198.03M2.16731,403 shs1.20 million shs
Travere Therapeutics, Inc. stock logo
RTRX
Travere Therapeutics
$15.30
+4.8%
$26.56
$8.98
$24.96
$781.10M0.67412,277 shs1.43 million shs
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
$1.22
+3.4%
$1.28
$0.70
$2.44
$14.12M0.59160,156 shs25,421 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Emisphere Technologies Inc. stock logo
EMIS
Emisphere Technologies
0.00%0.00%0.00%0.00%0.00%
Omeros Corporation stock logo
OMER
Omeros
+1.62%+5.39%-16.98%-51.85%-19.54%
Travere Therapeutics, Inc. stock logo
RTRX
Travere Therapeutics
-2.70%-1.32%-4.67%+3.22%+85.11%
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
+0.85%+4.42%-5.60%+32.58%-30.59%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Emisphere Technologies Inc. stock logo
EMIS
Emisphere Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
Omeros Corporation stock logo
OMER
Omeros
3.2683 of 5 stars
3.40.00.04.40.01.70.6
Travere Therapeutics, Inc. stock logo
RTRX
Travere Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Emisphere Technologies Inc. stock logo
EMIS
Emisphere Technologies
0.00
N/AN/AN/A
Omeros Corporation stock logo
OMER
Omeros
2.83
Moderate Buy$18.00432.54% Upside
Travere Therapeutics, Inc. stock logo
RTRX
Travere Therapeutics
0.00
N/AN/AN/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest OMER, TXMD, RTRX, and EMIS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/30/2025
Omeros Corporation stock logo
OMER
Omeros
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00
6/27/2025
Omeros Corporation stock logo
OMER
Omeros
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
6/10/2025
Omeros Corporation stock logo
OMER
Omeros
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$9.00
5/16/2025
Omeros Corporation stock logo
OMER
Omeros
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
5/13/2025
Omeros Corporation stock logo
OMER
Omeros
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
5/7/2025
Omeros Corporation stock logo
OMER
Omeros
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
4/11/2025
Omeros Corporation stock logo
OMER
Omeros
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Emisphere Technologies Inc. stock logo
EMIS
Emisphere Technologies
N/AN/AN/AN/AN/AN/A
Omeros Corporation stock logo
OMER
Omeros
N/AN/AN/AN/A($3.15) per shareN/A
Travere Therapeutics, Inc. stock logo
RTRX
Travere Therapeutics
$175.34M4.45N/AN/A$5.15 per share2.97
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
$1.84M7.67N/AN/A$2.37 per share0.51
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Emisphere Technologies Inc. stock logo
EMIS
Emisphere Technologies
N/AN/A0.00N/AN/AN/AN/AN/A
Omeros Corporation stock logo
OMER
Omeros
-$156.82M-$2.65N/AN/AN/AN/AN/A-59.68%8/6/2025 (Estimated)
Travere Therapeutics, Inc. stock logo
RTRX
Travere Therapeutics
-$146.43M-$3.46N/AN/AN/A-49.13%-36.38%-14.90%N/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
-$2.18MN/A0.00N/A-114.07%-7.86%-5.46%8/11/2025 (Estimated)

Latest OMER, TXMD, RTRX, and EMIS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Omeros Corporation stock logo
OMER
Omeros
-$0.46N/AN/AN/AN/AN/A
5/15/2025Q1 2025
Omeros Corporation stock logo
OMER
Omeros
-$0.60-$0.65-$0.05-$0.58$0.40 millionN/A
5/13/2025Q1 2025
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/A-$0.06N/A-$0.06N/A$0.39 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Emisphere Technologies Inc. stock logo
EMIS
Emisphere Technologies
N/AN/AN/AN/AN/A
Omeros Corporation stock logo
OMER
Omeros
N/AN/AN/AN/AN/A
Travere Therapeutics, Inc. stock logo
RTRX
Travere Therapeutics
N/AN/AN/AN/AN/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Emisphere Technologies Inc. stock logo
EMIS
Emisphere Technologies
N/AN/AN/A
Omeros Corporation stock logo
OMER
Omeros
N/A
1.16
1.16
Travere Therapeutics, Inc. stock logo
RTRX
Travere Therapeutics
0.66
7.23
7.14
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/A
2.64
2.64

Institutional Ownership

CompanyInstitutional Ownership
Emisphere Technologies Inc. stock logo
EMIS
Emisphere Technologies
N/A
Omeros Corporation stock logo
OMER
Omeros
48.79%
Travere Therapeutics, Inc. stock logo
RTRX
Travere Therapeutics
N/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
30.74%

Insider Ownership

CompanyInsider Ownership
Emisphere Technologies Inc. stock logo
EMIS
Emisphere Technologies
72.90%
Omeros Corporation stock logo
OMER
Omeros
12.90%
Travere Therapeutics, Inc. stock logo
RTRX
Travere Therapeutics
4.63%
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
2.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Emisphere Technologies Inc. stock logo
EMIS
Emisphere Technologies
6N/AN/ANot Optionable
Omeros Corporation stock logo
OMER
Omeros
21058.59 million51.04 millionOptionable
Travere Therapeutics, Inc. stock logo
RTRX
Travere Therapeutics
22151.05 millionN/ANot Optionable
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
42011.57 million11.31 millionOptionable

Recent News About These Companies

TherapeuticsMD Shifts Focus with Lower Q3 Losses
TherapeuticsMD Reports Reduced Losses Amid Strategic Shift
TherapeuticsMD Announces Third Quarter 2024 Financial Results
TherapeuticsMD (NASDAQ:TXMD) Stock, Option Chain

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Emisphere Technologies stock logo

Emisphere Technologies OTCMKTS:EMIS

$7.81 0.00 (0.00%)
As of 12/9/2020

Emisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. The company offers oral Eligen B12 Rx, an oral formulation prescription medical food for use by B12 deficient individuals. It is also developing GLP-1, which is in Phase III clinical trial for the treatment of type 2 diabetes and related conditions. The company's preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and pain, as well as in the development and expansion of nutritional supplement products. It has license agreements with Novo Nordisk A/S to develop and commercialize oral formulations of GLP-1 receptor agonists in combination with Emisphere carriers, as well as to develop and commercialize oral formulations of Novo Nordisk's insulin using the company's Eligen Technology. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is based in Roseland, New Jersey.

Omeros stock logo

Omeros NASDAQ:OMER

$3.38 +0.25 (+7.99%)
Closing price 04:00 PM Eastern
Extended Trading
$3.36 -0.02 (-0.59%)
As of 05:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Travere Therapeutics stock logo

Travere Therapeutics NASDAQ:RTRX

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

TherapeuticsMD stock logo

TherapeuticsMD NASDAQ:TXMD

$1.22 +0.04 (+3.39%)
Closing price 04:00 PM Eastern
Extended Trading
$1.20 -0.02 (-2.05%)
As of 05:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.